Stock Ratings / Health Care / ELAN / options

BMRN (74) RDY (64) SMMT (40) SYRE (55) ⌘ Pro Terminal →

Elanco Animal Health Incorporated (ELAN) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is ELAN trading relative to its 50-day, 200-day, and 52-week technical levels?

ELAN last traded at $23.06 (-0.77% on volume of 3,453,669 shares), positioning the stock +0.09% above its 50-day simple moving average ($23.04) and -3.03% below its 200-day simple moving average ($23.78). Across its 52-week range of $19.40 to $27.98, ELAN sits at the 42.7% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±5.9% ($21.70 to $24.42).

Q: What is ELAN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ELAN.

$23.06 -0.77% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.98

Elanco Animal Health Incorporated (ELAN) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $11.52B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELAN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELAN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Elanco Animal Health Incorporated (NYSE: ELAN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $23.06 (-0.77% 1D, market cap $11.52B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ELAN ranks #358 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELAN compare to BMRN and RDY in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELAN carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 55.0%, and ROIC of -2.5%. By comparison, BMRN (BioMarin Pharmaceutical Inc.) holds a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B) and RDY (Dr. Reddy's Laboratories Ltd) posts a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELAN?

▼

Per ELAN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739104), Elanco Animal Health Incorporated generated $4.71B in revenue (+6.2% YoY), -$232.0M in net income, and $284.0M in free cash flow against $13.36B in total assets and $3.06B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $22.98 (-0.33%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELAN)Realized 20D OHLCV Swing Band: ±5.9%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY ELAN SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 1.24 (DISTRESS RISK (<1.8)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (51.9) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$22.55+0% Next Q

Q2 (-2Q)

Grade D$22.55+0.4% Next Q

Q3 (-1Q)

Grade D$22.65+1.8% Next Q

Current

Grade D$23.06-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELAN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELAN currently carries a cautious 45/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.04) and Max Pain ($24.21) forces dealer call-delta covering toward $29.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELAN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELAN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±5.9%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ELAN)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ELAN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELAN)

✓Walkthrough of ELAN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELAN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.44%⚡ TESTING RESISTANCE

2026-11-03O $23.24H $23.24L $23.06C $23.06VOL 3.45M

RES: $23.65SUP: $21.81SMA50: $23.04SMA200: $23.78

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELAN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELAN Butterfly Map → + Track ELAN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

13.5%/yr Implied 5Y Growth

vs. +6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ELAN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELAN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELAN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELAN)

Health Care Rank #358 of 1016 ⚔️ BMRN vs ELAN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELAN vs. BMRN, RDY, SMMT, SYRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Elanco Animal Health Incorporated (ELAN) ranks #358 by composite RQD confidence (45/100, grade D) and #95 by equity capitalization ($11.52B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with ELAN at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELAN ACTIVE Elanco Animal Health Incorporated	D	45/100	—	55.0%	-2.5%	-0.77%	$11.52B	Benchmark Subject
BMRN BioMarin Pharmaceutical Inc.	B	74/100	31.9x	77.7%	6.0%	+1.77%	$11.33B	/bmrn-vs-elan →
RDY Dr. Reddy's Laboratories Ltd	C	64/100	32.8x	—	9.9%	+0.43%	$11.83B	/rdy-vs-elan →
SMMT Summit Therapeutics Inc.	D-	40/100	—	—	-35.0%	-1.05%	$12.82B	/smmt-vs-elan →
SYRE Spyre Therapeutics Inc.	D+	55/100	—	—	-20.0%	-2.42%	$10.08B	/syre-vs-elan →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001739104

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elanco Animal Health Incorporated (ELAN) reported GAAP revenue of $4.71B (+6.2% vs. FY2024 revenue of $4.44B , and +6.7% cumulative change since FY2023) , GAAP net income of -$232.0M, operating cash flow of $560.0M, and free cash flow of $284.0M (-27.9% YoY). On the balance sheet, ELAN closed FY2025 with $13.36B in total assets against $3.06B in total debt (Altman Z-Score: 1.24, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$4.71B	-$232.0M	$560.0M	$284.0M	$13.36B	$3.06B
FY2024 (FY)	2024-12-31	$4.44B	$338.0M	$541.0M	$394.0M	$12.61B	$4.28B
FY2023 (FY)	2023-12-31	$4.42B	-$1.23B	$271.0M	$72.2M	$6.39B	$1.49B

3. ELAN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELAN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ELAN compare to BMRN and RDY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ELAN?

Where is ELAN trading relative to its 50-day, 200-day, and 52-week technical levels?

ELAN last traded at $23.06 (-0.77% on volume of 3,453,669 shares), positioning the stock +0.09% above its 50-day simple moving average ($23.04) and -3.03% below its 200-day simple moving average ($23.78). Across its 52-week range of $19.40 to $27.98, ELAN sits at the 42.7% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±5.9% ($21.70 to $24.42).

ELAN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ELAN's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ELAN.

Direct Sub-Reports: ELAN RQD Cockpit ELAN 12M Forecast ELAN Earnings & Move ELAN Dividends & DRIP ELAN Insiders & 13F ELAN Whale Options ELAN Profit Sankey ELAN News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ELAN — Elanco Animal Health Incorporated: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:15:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ELAN scores 47 out of 100 with a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 9 / 20. Per the RQD rating, this pillar reflects ROIC of -2.5% and an FCF yield of 2.45%. Negative ROIC means the business is not currently earning returns above its capital base, a core weakness for a prospective buyer assessing whether growth is value-creating.
Whale / 13F Flow: 11 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The source data contains no 13F detail (see Analyst View section), so the score cannot be traced to specific holders.
Insider Conviction: 12 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. No underlying insider transactions are provided in the source data.
Macro Regime Fit: 5 / 20. Per the RQD rating, this is the lowest pillar, reflecting a beta of 0.96 and sector sensitivity. A beta near 1.0 means the stock is expected to move roughly in line with the broad market, so this score points to weak alignment with the current macro regime rather than volatility risk.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, this reflects an Altman Z of 1.24, Piotroski F of 7/9, and Debt/Equity of 0.44. The Piotroski reading is comparatively strong, but the Altman figure sits in a range generally treated as distress-adjacent, which weighs on the score.

Translating these into investor implications: the RQD profile shows a company whose operating economics are currently negative (ROIC -2.5%, net margin -4.9%) with only moderate balance sheet support. Upside drivers would need to come from margin recovery and sustained free cash flow; the forward P/E of 20 implies the market is already pricing in some earnings improvement relative to trailing EPS of -0.46. The valuation tradeoff is that a positive forward multiple on negative trailing earnings depends heavily on that recovery materializing. The low Macro Regime score suggests limited tailwind from sector positioning. This is an educational reading of the rating, not personalized advice.

Business

Elanco Animal Health Incorporated is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile identifies the company as operating in animal health. Specific product lines, customer segments, and revenue mix are not available in source data. The company carries a market capitalization of $11.6B per the profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$4715.0M	$-273.8M	$-232.0M	N/A	$284.0M	$545.0M	$3064.9M
FY 2024	$4439.0M	$398.8M	$338.0M	N/A	$394.0M	$468.0M	$4277.0M
FY 2023	$4417.0M	$-1452.6M	$-1231.0M	N/A	$72.2M	N/A	$1494.4M

Per the SEC financials, revenue rose from $4417.0M in FY 2023 to $4715.0M in FY 2025, while operating income swung from $398.8M in FY 2024 to $-273.8M in FY 2025. Per the market data, gross margin is 55%, operating margin is -6%, and net margin is -4.9%, with ROIC at -2.5%. Per the RQD rating, the Altman Z-Score is 1.24 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.44. Reported debt declined from $4277.0M in FY 2024 to $3064.9M in FY 2025 while cash rose to $545.0M.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items reference ELAN. Five are tagged as market wire and one as a catalyst. The catalyst-tagged item carries a GREEN light, a Yahoo Finance report on whether ELAN will beat estimates in its next earnings report. Four other items are general market-action summaries from Yahoo! Finance Canada, TradingView, Stock Titan, and Simply Wall St, each flagged YELLOW. A Yahoo Finance earnings preview ("Earnings Expected to Grow") is also flagged YELLOW. The feed does not disclose specific earnings figures, guidance, or event details. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are mapped for ELAN.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are not available in source data. Investors should note that the absence of mapped links is a data gap, not evidence of an absence of dependencies.

Open Questions

What are the specific drivers of the FY 2025 swing from positive operating income in FY 2024 to a negative operating result?
What are the trailing P/E and EV/EBITDA values, which the source data marks as unavailable?
What specific institutional, insider, or Congressional transactions underlie the whale and insider pillar scores?
What is the company's debt maturity profile and interest coverage, given the reported debt of $3064.9M against cash of $545.0M?
Which upstream suppliers and downstream customers drive revenue, and how exposed is the business to them?

ELAN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Elanco Animal Health Incorporated (ELAN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ELAN Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 17h ago

Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 20h ago

Elanco Animal Health Incorporated Estimates – NYSE:ELAN

TradingView report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Yahoo Finance report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Elanco Animal Health Incorporated (ELAN) Stock Price, News & Analysis

Stock Titan report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Elanco Animal Health (NYSE:ELAN) Stock Price

Simply Wall St report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?

Yahoo Finance report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Elanco Animal Health Incorporated (ELAN) Affects Rotational Strategy Timing

Stock Traders Daily report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Elanco's people chief retires at year-end; Jamie Preston starts Nov. 3.

Stock Titan report covering Elanco Animal Health Incorporated (ELAN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ELAN Bull vs. Bear Conversation Board — What's Your Call at $23.06?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ELAN 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $25.10 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ELAN (D • RQD 47/100) a Buy at $23.24?

Welcome to the ELAN (Elanco Animal Health Incorporated) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $18.13 (-22.0%)

Spot @ $23.24

Pump the brakes on ELAN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ELAN, but look at what you are paying: current EV/EBITDA multiples with 55.0% gross margins. Unless Elanco Animal Health Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $27.89 (+20.0%)

Spot @ $23.24

ELAN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ELAN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $23.24 (52-wk range $19.40 - $27.98), any beat on forward guidance forces shorts and underweight funds to chase.